RxDoctor Payments Data

Hazem Ali, MD

Clinical Neurophysiology · Lynbrook, NYNPI 1578695474

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 52.6% of the total. That places this record below the midpoint for clinical neurophysiology clinicians in NY, where the typical reported total is $1,360.

$542in general payments, 2019–2025

Across 26 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$285
  • Pfizer$107
  • UCB, Inc.$34
  • Lilly USA, LLC$27
  • Supernus Pharmaceuticals, Inc.$26
  • SK Life Science, Inc.$25
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$542100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$542 in reported general payments places this provider in the 25th percentile of 35 clinical neurophysiology providers in New York.

See all clinical neurophysiology providers in New York

Medicare billing

Part B allowed, 2024
$15,083
Medicare patients
29
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium222$76,738
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate17$58,606
Diclofenac Potassium67$29,120
ZtlidoLidocaine51$17,719
LyricaPregabalin11$9,498
LinzessLinaclotide18$9,033
Pregabalin442$6,427
Colchicine214$3,979
Lidocaine33$3,680
Metformin Hcl15$3,551
Lactulose12$2,902
Selegiline Hcl75$2,449
Memantine Hcl299$2,226
Gabapentin231$1,134
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone11$965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerLyrica$107$9,49811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 35 clinical neurophysiology providers in New York.

Other clinical neurophysiology in Lynbrook

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →